Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950163 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL7163906 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31470993 | 0.93 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30604630 | 0.93 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL120580 | 0.93 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29400883 | 0.91 | KMT2A (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL6520211 | 0.91 | KMT2A (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL12787768 | 0.89 | CASP3 (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL15883257 | 0.89 | CASP3 (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30645104 | 0.89 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023108031-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-3924058-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167706-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200255403-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-2882439-A1 | APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028381-A1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255403-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, NPY5R | CASP3 3800/4885KMT2A 1675/4885MDM4 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.